论文部分内容阅读
目的探讨肿瘤标志物糖类抗原CA19-9在诊断早期胰腺癌(PCA)中的作用。方法选取2009年3月至2010年10月间收治的35例胰腺癌患者为观察组,同时选择40位健康者为对照组。以化学发光免疫分析法对两组肿瘤标志物糖类抗原CA19-9水平进行检测并分析检测结果。结果观察组患者血清CA19-9阳性率为86.9%,对照组阳性率为7.3%,两组比较差异有统计学意义(P<0.05)。结论针对早期胰腺癌的检查,CA19-9检测有非常明显的临床价值,应该作为早期胰腺癌检查的可靠指标。
Objective To investigate the role of tumor marker carbohydrate antigen CA19-9 in the diagnosis of early pancreatic cancer (PCA). Methods Thirty-five patients with pancreatic cancer who were treated between March 2009 and October 2010 were selected as observation group and 40 healthy persons as control group. Chemiluminescent immunoassay was used to detect the level of carbohydrate antigen CA19-9 in two groups of tumor markers and the test results were analyzed. Results In the observation group, the positive rate of serum CA19-9 was 86.9%, while the positive rate of the control group was 7.3%. There was significant difference between the two groups (P <0.05). Conclusion For early pancreatic cancer examination, CA19-9 test has a very significant clinical value, should be used as a reliable indicator of early pancreatic cancer examination.